Semaglutide GLP-1 Analogue 5mg

$114.99 Sale Save

Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 receptor agonist). It has been approved as a second line treatment option for better glycaemic control in type 2 diabetes and currently under scrutiny for anti-obesity purpose. Semaglutide has been proved to be safe in adults and elderly patients with renal or hepatic disorders demanding no dose modification. Cardiovascular (CV) outcome trials established that it can reduce various CV risk factors in patients with established CV disorders. Semaglutide is well tolerated with no risk of hypoglycaemia in monotherapy but suffers from gastrointestinal adverse effects. A large population affected with COVID-19 infection were diabetic; therefore use of semaglutide in diabetes as well as CV patients would be very much supportive in maintaining health care system during this pandemic situation. Hence, this peptidic drug can be truly considered as a quintessential of GLP-1 agonists for management of type 2 diabetes.

Product text

DISCLAIMER: By purchasing peptides from Pro Peptide Research Lab, you acknowledge and agree that these products are intended for research purposes only and are not intended for human consumption or use as a dietary supplement. This product is sold as a pure compound for research purposes only. You assume full responsibility for the proper handling, storage, and use of these research chemicals. Pro Peptide Research Lab shall not be held liable for any misuse, improper handling, or unauthorized use of the research chemicals purchased by you, the consumer. It is your responsibility to adhere to all applicable laws and regulations regarding the use and handling of research chemicals. Prior to purchase, we recommend reviewing our terms and conditions. Additionally, please keep these products out of reach from children to ensure their safety.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)